Holen Sie sich die Stockscreener-App
16.69
14.41%
-2.81
Handel nachbörslich:
16.90
0.21
+1.26%
Schlusskurs vom Vortag:
$19.50
Offen:
$19.35
24-Stunden-Volumen:
266.07K
Relative Volume:
1.48
Marktkapitalisierung:
$868.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-41.43M
KGV:
-21.13
EPS:
-0.79
Netto-Cashflow:
$-39.97M
1W Leistung:
+4.38%
1M Leistung:
+35.58%
6M Leistung:
+89.66%
1J Leistung:
+39.67%
1-Tages-Spanne:
$16.51
$19.35
1-Wochen-Bereich:
$16.05
$19.51
52-Wochen-Spanne:
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Vergleichen Sie GHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
16.69 | 991.85M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2025-03-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-02-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-08-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-16 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Gh Research Plc Aktie (GHRS) Neueste Nachrichten
Is GH Research PLC a good long term investmentPhenomenal returns - jammulinksnews.com
GH Research PLC Stock Analysis and ForecastFree Real-Time Stock Data - jammulinksnews.com
What drives GH Research PLC stock priceFree High-Return Strategy Alerts - jammulinksnews.com
What analysts say about GH Research PLC stockUnprecedented market success - printweek.in
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) With Overweight Rating - MSN
What analysts say about WSO.B stockTremendous wealth creation - Autocar Professional
Best IPO Stocks in India Premium Stock Trading StrategiesLightning-fast capital gains - PrintWeekIndia
Punjab Communications Limited (500346)’s Trend in 2025Market-leading profit generation - Autocar Professional
Top Mining Stocks in India Professional Stock AnalysisGame-changing capital returns - PrintWeekIndia
Is LWLG a good long term investmentSuperior stock selection - jammulinksnews.com
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade - MSN
Why GH Research PLC stock attracts strong analyst attentionProven Trading Plan - Newser
What drives ARGO.PRA stock priceRapid portfolio appreciation - jammulinksnews.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
What institutions are buying MFS Charter Income Trust stock nowSafer Investing With Bigger Upside - Newser
FY2025 EPS Estimates for GH Research Lifted by HC Wainwright - Defense World
Is It Worth Buying EUL(eulerfinance)Weekly Double Return List - Newser
(GHRS) Long Term Investment Analysis - news.stocktradersdaily.com
What makes GH Research PLC stock price move sharplyFree Market Dynamics Reports - Newser
How GH Research PLC stock performs during market volatilityFree Wealth-Building Investment Strategies - Newser
What makes First Seacoast Bancorp Inc. stock price move sharplyVerified Return Tips - newser.com
GH Research stock awaits FDA response on clinical hold, says Canaccord - Investing.com Nigeria
Quicker Psychedelic Drugs Offer Investors a Better Trip - Bloomberg
Long Term Trading Analysis for (GHRS) - news.stocktradersdaily.com
Compass Pathways: Psychedelics Drug Data Sends Share Price SouthRating Downgrade (CMPS) - Seeking Alpha
JMP reiterates GH Research stock rating on competitor’s positive results - Investing.com
JMP reiterates GH Research stock rating on competitor’s positive results By Investing.com - Investing.com UK
Compass Pathways stock slip as psilocybin depression trial falls short of expectations - TradingView
Health Care Stocks Stumble Amid Market Adjustments - Finimize
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule - The Manila Times
Finanzdaten der Gh Research Plc-Aktie (GHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):